CA2968301C - 5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators - Google Patents
5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators Download PDFInfo
- Publication number
- CA2968301C CA2968301C CA2968301A CA2968301A CA2968301C CA 2968301 C CA2968301 C CA 2968301C CA 2968301 A CA2968301 A CA 2968301A CA 2968301 A CA2968301 A CA 2968301A CA 2968301 C CA2968301 C CA 2968301C
- Authority
- CA
- Canada
- Prior art keywords
- general formula
- compound
- alkyl
- process according
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1420594.2A GB201420594D0 (en) | 2014-11-19 | 2014-11-19 | Compounds |
| GB1420593.4 | 2014-11-19 | ||
| GB1420594.2 | 2014-11-19 | ||
| GBGB1420593.4A GB201420593D0 (en) | 2014-11-19 | 2014-11-19 | Compounds |
| GBGB1505674.0A GB201505674D0 (en) | 2015-04-01 | 2015-04-01 | Compounds |
| GB1505674.0 | 2015-04-01 | ||
| PCT/GB2015/053517 WO2016079518A1 (en) | 2014-11-19 | 2015-11-19 | 5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2968301A1 CA2968301A1 (en) | 2016-05-26 |
| CA2968301C true CA2968301C (en) | 2023-05-16 |
Family
ID=54704020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2968301A Active CA2968301C (en) | 2014-11-19 | 2015-11-19 | 5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10131688B2 (https=) |
| EP (1) | EP3221332B1 (https=) |
| JP (1) | JP6724004B2 (https=) |
| KR (1) | KR102526632B1 (https=) |
| CN (1) | CN107108687B (https=) |
| CA (1) | CA2968301C (https=) |
| DK (1) | DK3221332T3 (https=) |
| EA (1) | EA033445B1 (https=) |
| ES (1) | ES2733643T3 (https=) |
| HK (1) | HK1244285B (https=) |
| MX (1) | MX375864B (https=) |
| PL (1) | PL3221332T3 (https=) |
| TW (1) | TWI686400B (https=) |
| WO (1) | WO2016079518A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107207559B (zh) | 2014-11-19 | 2019-10-25 | Nzp英国有限公司 | 作为制备类固醇fxr调节剂的中间体的6-烷基-7-羟基-4-烯-3-酮类固醇 |
| KR102527821B1 (ko) | 2014-11-19 | 2023-05-02 | 엔제트피 유케이 리미티드 | 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-6,7-다이온 스테로이드 |
| KR102546748B1 (ko) | 2014-11-19 | 2023-06-22 | 엔제트피 유케이 리미티드 | 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-3,7-다이온 스테로이드 |
| JP2018538331A (ja) * | 2015-12-22 | 2018-12-27 | インターセプト ファーマシューティカルズ, インコーポレイテッド | オベチコール酸の多型結晶形態 |
| GB201608779D0 (en) * | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Methods and compounds |
| GB201608776D0 (en) | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Methods and compounds |
| GB201608777D0 (en) | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Compounds |
| CN106279331B (zh) * | 2016-07-27 | 2019-06-14 | 宋火良 | 胆酸类肝病治疗药物 |
| EP3431486A1 (en) * | 2017-07-18 | 2019-01-23 | Bionice, S.L.U. | Process and intermediates for the synthesis of obeticholic acid and derivatives thereof |
| GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
| CN111138509B (zh) * | 2018-11-02 | 2022-12-06 | 东莞东阳光药物研发有限公司 | 奥贝胆酸的制备方法 |
| CN113135970B (zh) * | 2020-01-20 | 2024-11-22 | 成都贝诺科成生物科技有限公司 | 一种具有抗芽孢活性的化合物及其药用组合物 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2624748A (en) | 1950-09-09 | 1953-01-06 | Upjohn Co | Bisnorchola-4, 6-dien-3-one-22-al |
| US4289872A (en) | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
| US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
| CA2118130A1 (en) | 1992-04-14 | 1993-10-28 | Jean M. J. Frechet | Dendritic based macromolecules and method of production |
| WO1994019366A1 (en) | 1993-02-26 | 1994-09-01 | Magainin Pharmaceuticals Inc. | Chemical synthesis of squalamine |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| ES2248581T3 (es) | 2001-03-12 | 2006-03-16 | Intercept Pharmaceuticals, Inc. | Esteroides como agonistas de fxr. |
| US20090062256A1 (en) | 2001-06-01 | 2009-03-05 | Bristol-Myers Squibb Pharma Company | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION |
| AU2002352524B2 (en) | 2001-11-07 | 2007-10-04 | Nektar Therapeutics | Branched polymers and their conjugates |
| EP1568706A1 (en) | 2004-02-26 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Novel steroid agonist for FXR |
| ITMI20050912A1 (it) * | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
| JP2007210888A (ja) * | 2006-01-12 | 2007-08-23 | Mitsubishi Chemicals Corp | ステロイド化合物の製造方法 |
| CN101395170A (zh) | 2006-02-14 | 2009-03-25 | 英特塞普特药品公司 | 用于预防或治疗fxr介导的疾病或状态的作为fxr配体的胆汁酸衍生物 |
| US7932244B2 (en) | 2006-06-27 | 2011-04-26 | Intercept Pharmaceuticals, Inc. | Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions |
| KR101555716B1 (ko) | 2007-01-19 | 2015-09-25 | 인터셉트 파마슈티컬즈, 인크. | Tgr5 조절제로서의 23-치환 담즙산 및 이의 사용 방법 |
| WO2010014836A2 (en) * | 2008-07-30 | 2010-02-04 | Intercept Pharmaceuticals, Inc. | Tgr5 modulators and methods of use thereof |
| DK2698375T3 (en) | 2008-11-19 | 2018-05-28 | Intercept Pharmaceuticals Inc | TGR5 modulators and methods for using them |
| ES2774368T3 (es) * | 2008-11-19 | 2020-07-20 | Intercept Pharmaceuticals Inc | Moduladores de TGR5 y métodos de uso de los mismos |
| EP2459581A4 (en) | 2009-07-29 | 2012-12-26 | Univ Chicago | LIVER X-RECEPTOR AGONISTS |
| SI3336097T1 (sl) | 2012-06-19 | 2021-07-30 | Intercept Pharmaceuticals, Inc. | Priprava nekristalinične oblike obetiholne kisline |
| SG11201503247UA (en) | 2012-10-26 | 2015-06-29 | Intercept Pharmaceuticals Inc | Process for preparing bile acid derivatives |
| AU2013352288B2 (en) | 2012-11-28 | 2017-11-23 | Intercept Pharmaceuticals, Inc. | Treatment of pulmonary disease |
| US20140206657A1 (en) * | 2013-01-18 | 2014-07-24 | City Of Hope | Bile acid analog tgr5 agonists |
| TN2015000497A1 (en) | 2013-05-14 | 2017-04-06 | Intercept Pharmaceuticals Inc | 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators |
| SG11201509371XA (en) | 2013-05-24 | 2015-12-30 | Nestec Sa | Pathway specific markers for diagnosing irritable bowel syndrome |
| US10166246B2 (en) | 2014-05-27 | 2019-01-01 | City Of Hope | TGR5 agonist complexes for treating diabetes and cancer |
| SMT202000070T1 (it) | 2014-05-29 | 2020-03-13 | Bar Pharmaceuticals S R L | Derivati del colano per l'uso del trattamento e/o la prevenzione di malattie mediate da fxr e tgr5/gpbar1 |
| SG11201703717SA (en) | 2014-11-06 | 2017-06-29 | Enanta Pharm Inc | Bile acid analogs an fxr/tgr5 agonists and methods of use thereof |
| KR102546748B1 (ko) | 2014-11-19 | 2023-06-22 | 엔제트피 유케이 리미티드 | 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-3,7-다이온 스테로이드 |
| CN107207559B (zh) | 2014-11-19 | 2019-10-25 | Nzp英国有限公司 | 作为制备类固醇fxr调节剂的中间体的6-烷基-7-羟基-4-烯-3-酮类固醇 |
| KR102527821B1 (ko) | 2014-11-19 | 2023-05-02 | 엔제트피 유케이 리미티드 | 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-6,7-다이온 스테로이드 |
| WO2016079527A1 (en) | 2014-11-19 | 2016-05-26 | Tetralogic Birinapant Uk Ltd | Combination therapy |
| EP3223823A4 (en) | 2014-11-26 | 2018-10-17 | Enanta Pharmaceuticals, Inc. | Bile acid analogs as fxr/tgr5 agonists and methods of use thereof |
| US11578097B2 (en) | 2014-11-26 | 2023-02-14 | Enanta Pharmaceuticals, Inc. | Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| WO2016086134A1 (en) | 2014-11-26 | 2016-06-02 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| CN106279328A (zh) | 2015-05-20 | 2017-01-04 | 重庆药友制药有限责任公司 | 一种制备6α-烷基鹅去氧胆酸的方法 |
| JP6861703B2 (ja) | 2015-06-19 | 2021-04-21 | インターセプト ファーマシューティカルズ, インコーポレイテッド | Tgr5修飾物質およびその使用方法 |
| CN106397522A (zh) | 2015-07-31 | 2017-02-15 | 中国人民解放军军事医学科学院毒物药物研究所 | 3,7‑二(叔丁基二甲基硅基氧基)‑6‑烯‑5β‑胆烷‑24‑酸甲酯 |
| CN106478759A (zh) | 2015-08-31 | 2017-03-08 | 陕西合成药业股份有限公司 | 奥贝胆酸衍生物及其制备方法和用途 |
| CN106478756A (zh) | 2015-09-02 | 2017-03-08 | 中美华世通生物医药科技(武汉)有限公司 | Oca-e单晶及其制备方法和用途 |
| CN106518946A (zh) | 2015-09-10 | 2017-03-22 | 上海迪诺医药科技有限公司 | 磺酰脲衍生物、其药物组合物及应用 |
-
2015
- 2015-11-19 EA EA201790881A patent/EA033445B1/ru unknown
- 2015-11-19 KR KR1020177016856A patent/KR102526632B1/ko active Active
- 2015-11-19 WO PCT/GB2015/053517 patent/WO2016079518A1/en not_active Ceased
- 2015-11-19 TW TW104138184A patent/TWI686400B/zh not_active IP Right Cessation
- 2015-11-19 DK DK15800910.0T patent/DK3221332T3/da active
- 2015-11-19 MX MX2017006564A patent/MX375864B/es active IP Right Grant
- 2015-11-19 JP JP2017527816A patent/JP6724004B2/ja active Active
- 2015-11-19 EP EP15800910.0A patent/EP3221332B1/en active Active
- 2015-11-19 CN CN201580062893.5A patent/CN107108687B/zh active Active
- 2015-11-19 HK HK18103791.5A patent/HK1244285B/en unknown
- 2015-11-19 ES ES15800910T patent/ES2733643T3/es active Active
- 2015-11-19 US US15/528,220 patent/US10131688B2/en active Active
- 2015-11-19 PL PL15800910T patent/PL3221332T3/pl unknown
- 2015-11-19 CA CA2968301A patent/CA2968301C/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017538691A (ja) | 2017-12-28 |
| EP3221332A1 (en) | 2017-09-27 |
| US20170320907A1 (en) | 2017-11-09 |
| EA201790881A8 (ru) | 2019-07-31 |
| TWI686400B (zh) | 2020-03-01 |
| CN107108687B (zh) | 2019-10-29 |
| JP6724004B2 (ja) | 2020-07-15 |
| US10131688B2 (en) | 2018-11-20 |
| ES2733643T3 (es) | 2019-12-02 |
| PL3221332T3 (pl) | 2019-10-31 |
| EP3221332B1 (en) | 2019-04-24 |
| WO2016079518A1 (en) | 2016-05-26 |
| KR102526632B1 (ko) | 2023-04-27 |
| CN107108687A (zh) | 2017-08-29 |
| MX2017006564A (es) | 2018-01-26 |
| KR20170099895A (ko) | 2017-09-01 |
| EA201790881A1 (ru) | 2017-11-30 |
| DK3221332T3 (da) | 2019-07-29 |
| TW201629081A (zh) | 2016-08-16 |
| EA033445B1 (ru) | 2019-10-31 |
| CA2968301A1 (en) | 2016-05-26 |
| MX375864B (es) | 2025-03-07 |
| HK1244285B (en) | 2020-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2968301C (en) | 5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators | |
| EP3221331B1 (en) | 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators | |
| EP3221333B1 (en) | 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal fxr modulators | |
| EP3221334B1 (en) | 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators | |
| HK1244285A1 (en) | 5.beta -6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators | |
| HK1246801B (en) | 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators | |
| HK1244287B (en) | 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal fxr modulators | |
| NZ731924B2 (en) | 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators | |
| HK1244286B (en) | 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20201118 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241115 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241115 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260108 |